Nanogroup SA (NNG) - Total Assets
Based on the latest financial reports, Nanogroup SA (NNG) holds total assets worth zł16.63 Million PLN (≈ $4.58 Million USD) as of June 2025. Total assets represent everything the company owns and controls, combining both current assets—like cash and cash equivalents, accounts receivable, and inventories—and non-current assets such as property, plant, equipment (PP&E), intangible assets, and long-term investments. See Nanogroup SA net assets for net asset value and shareholders' equity analysis.
Nanogroup SA - Total Assets Trend (2014–2024)
This chart illustrates how Nanogroup SA's total assets have evolved over time, based on quarterly financial data.
Nanogroup SA - Asset Composition Analysis
Current Asset Composition (December 2024)
Nanogroup SA's total assets of zł16.63 Million consist of 47.3% current assets and 52.7% non-current assets.
| Asset Category | Amount (PLN) | % of Total Assets |
|---|---|---|
| Cash & Equivalents | zł0.00 | 39.3% |
| Accounts Receivable | zł205.17K | 1.0% |
| Inventory | zł36.20K | 0.2% |
| Property, Plant & Equipment | zł0.00 | 0.0% |
| Intangible Assets | zł9.94 Million | 49.9% |
| Goodwill | zł0.00 | 0.0% |
Asset Composition Trend (2014–2024)
This chart illustrates how Nanogroup SA's asset composition has evolved over time. Understanding changes in asset allocation can provide insights into the company's strategic shifts, capital allocation priorities, and business focus evolution. For live market cap, price, and company overview, see market cap of Nanogroup SA.
Key Asset Composition Facts
- Current vs. Non-Current Assets: Nanogroup SA's current assets represent 47.3% of total assets in 2024, a decrease from 47.9% in 2014.
- Cash Position: Cash and equivalents constituted 39.3% of total assets in 2024, up from 33.1% in 2014.
- Tangible vs. Intangible: Intangible assets (including goodwill) make up 49.0% of total assets, an increase from 38.0% in 2014.
- Asset Diversification: The largest asset category is intangible assets at 49.9% of total assets.
Nanogroup SA Competitors by Total Assets
Key competitors of Nanogroup SA based on total assets are shown below.
| Company | Country | Total Assets |
|---|---|---|
|
Argen-X
F:1AE
|
Germany | €7.18 Billion |
|
Tubize-Fin
BR:TUB
|
Belgium | €1.93 Billion |
|
BrightGene Bio Medical Technology C
SHG:688166
|
China | CN¥5.38 Billion |
|
Dashenlin Pharm Grp Co Ltd
SHG:603233
|
China | CN¥26.08 Billion |
|
Staidson Beijing Biopharma
SHE:300204
|
China | CN¥1.26 Billion |
|
Tibet Cheezheng Tibetan Medicine Co Ltd
SHE:002287
|
China | CN¥6.64 Billion |
|
Ardelyx Inc
NASDAQ:ARDX
|
USA | $486.17 Million |
|
Xiangxue Pharmaceutical
SHE:300147
|
China | CN¥7.36 Billion |
Nanogroup SA - Liquidity and Working Capital Analysis
Liquidity ratios measure a company's ability to pay off its short-term debts as they come due, using the company's current or quick assets. Working capital represents the operational liquidity available.
Key Liquidity Metrics
| Metric | Current | 1 Year Ago | 5 Years Ago |
|---|---|---|---|
| Current Ratio | 1.40 | 2.76 | 1.09 |
| Quick Ratio | 1.33 | 2.75 | 1.05 |
| Cash Ratio | 0.00 | 0.00 | 0.00 |
| Working Capital | zł844.00K | zł1.65 Million | zł58.96K |
Nanogroup SA - Advanced Valuation Insights
This section examines the relationship between Nanogroup SA's asset base and its market valuation, helping to identify whether the company's assets are efficiently translated into market value.
Key Valuation Metrics
| Current Price-to-Book Ratio | 6.63 |
| Latest Market Cap to Assets Ratio | 1.11 |
| Asset Growth Rate (YoY) | 131.0% |
| Total Assets | zł19.94 Million |
| Market Capitalization | $22.04 Million USD |
Valuation Analysis
Above Book Valuation: The market values Nanogroup SA's assets above their book value (1.11x), reflecting positive investor sentiment about the company's future prospects.
Rapid Asset Growth: Nanogroup SA's assets grew by 131.0% over the past year, indicating significant expansion of the company's resource base.
Annual Total Assets for Nanogroup SA (2014–2024)
The table below shows the annual total assets of Nanogroup SA from 2014 to 2024.
| Year | Total Assets | Change |
|---|---|---|
| 2024-12-31 | zł19.94 Million ≈ $5.49 Million |
+130.97% |
| 2023-12-31 | zł8.63 Million ≈ $2.38 Million |
-55.04% |
| 2022-12-31 | zł19.20 Million ≈ $5.28 Million |
-5.43% |
| 2021-12-31 | zł20.30 Million ≈ $5.59 Million |
-32.41% |
| 2020-12-31 | zł30.04 Million ≈ $8.27 Million |
+13.88% |
| 2019-12-31 | zł26.38 Million ≈ $7.26 Million |
-2.44% |
| 2018-12-31 | zł27.04 Million ≈ $7.44 Million |
+19.60% |
| 2017-12-31 | zł22.61 Million ≈ $6.22 Million |
+16.21% |
| 2016-12-31 | zł19.45 Million ≈ $5.35 Million |
+236.38% |
| 2015-12-31 | zł5.78 Million ≈ $1.59 Million |
+387.10% |
| 2014-12-31 | zł1.19 Million ≈ $326.74K |
-- |
About Nanogroup SA
NanoGroup S.A. operates as a biotechnology company in Poland. The company develops and licenses early-stage pre-clinical and IND solutions to international biotech and pharma companies. It also manages a portfolio of companies that manages projects for the need of modern medicine in the field of oncology and transplantology. The company was incorporated in 2016 and is based in Warsaw, Poland.